Some insight in such difficult-to-treat melanoma patients was gained through the COMBI-mb trial, recruiting within four cohorts 125 patients in total with either asymptomatic (pre-/untreated), rare mutation types (other than BRAF V600) or symptomatic brain mutations arising from melanoma [13]. Here, BRAF is linked to melanoma.